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Ethanol Pharmacokinetics in Neonates Secondary to Medication Administration 
Elizabeth Marek1, Susan C. Adeniyi-Jones2, Lindsey Roke3, Tara E. DeCerbo3, Rebecca L. Cordell4, Paul S. Monks4 and Walter K. Kraft1 
Abstract 
Purpose: 
Ethanol serves as a solvent and microbial preservative in oral liquid medications and is the second 
most commonly used solvent in liquid medications following water. Despite widespread use of ethanol 
in liquid medications for neonates, the pharmacokinetics and toxicity of ethanol in young children are 
not well described. The aim of the current study is to quantify blood ethanol levels in neonates 
secondary to oral ethanol containing medications. 
Methods: 
Neonates who received either oral phenobarbital (15% ethanol) and/or oral dexamethasone (30% 
ethanol) per standard of care were eligible for enrollment. A maximum of 6 blood samples per patient 
(4.5 mL total) were taken over the study period. Blood samples were collected via heel stick at the 
time of clinical laboratory collections or following a specific collection for study purposes. In addition, 
blood samples were collected from neonates receiving sublingual buprenorphine (30% ethanol) for 
neonatal abstinence syndrome from a separate clinical study. Blood ethanol levels were measured 
using a validated headspace gas chromatography-mass spectrometry method utilizing micro-volume 
(  ̴100uL) plasma samples. The limit of detection and lower limit of quantification for the assay were 
0.1 mg/L and 0.5 mg/L respectively.  
Results: 
A total of 39 plasma samples from 15 neonates who were on ethanol containing medications were 
collected over the study period. Four neonates were exposed to phenobarbital and/or 
dexamethasone, while eleven neonates were exposed to buprenorphine alone or in combination with 
phenobarbital. Patients were exposed to an average of 71.6 mg/kg (range 13.1 to 215 mg/kg) of 
ethanol after a single dose of an ethanol containing medication.  Blood ethanol levels were detectable 
in 98% (38/39) of samples, quantifiable in 67% (26/39) of samples, and ranged from below detection 
to 85.4 mg/L. Ethanol was rapidly cleared and did not accumulate with current dosing regimens.  
Conclusion: 
Ethanol intake secondary to medication administration varied widely. Blood ethanol levels in neonates 
were low and ethanol was eliminated rapidly after a single dose of oral medications that contained a 
sizable fraction of ethanol.  
 Patient Baseline Characteristics 
Sample Collection 
Concentration-Time Profiles  
Conclusion & Future Directions 
Future Directions 
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Figure 8:  Plasma sample collection.  A total of 39 plasma samples from 15 neonates were collected over the study period. 
*Eliminated from further analysis due to overlapping medication administration times.   
Methods 
Characteristic 
Mean ± SD or Number 
Morphine  
“Control”  
(n=14) 
Buprenorphine 
“Ethanol” 
 (n=12) 
Birth weight (g) 2900.8 ± 453.2 2935.5 ± 361.4 
Gestational age (wk) 39.1 ± 1.2 38.9 ± 1.4 
Postnatal age (day) 13.3 ± 5.0 12.2 ± 5.5 
Postmenstrual age (wk) 41.1 ± 1.3 40.7 ± 0.4 
Sex 
Male/Female 7/7 5/7 
Race 
Black/White 0/14 3/9 
Characteristic 
Mean ± SD or Number 
Phenobarbital or Dexamethasone 
“Ethanol” 
(n=3) 
Birth weight (g) 1858 ± 1540.1 
Gestational age (wk) 31.1 ± 5.9 
Postnatal age (day) 28.3 ± 2.1 
Postmenstrual age (wk) 35.2 ± 5.6 
Sex 
Male/Female 2/1 
Race 
Black/White 3/0 
Figure 4.  Patient baseline characteristics (at first blood draw) in Study #1.  
Figure 3.  Endogenous ethanol production in neonates (n=30 samples 
from 14 neonates).  Samples were obtained from neonates in Study #2 
who were on morphine.  Patients did not receive any ethanol containing 
medications.   
• Endogenous blood 
ethanol levels ranged 
from below the LLOQ 
to 3.65 mg/L in 
neonates 
-Mean: 0.63 mg/L 
-Median:  0.44 mg/L 
• For reference, 
previous studies have 
shown levels below 
detection (0.05 mg/L) 
to 1.6 mg/L in adults1 
Endogenous Ethanol Production 
in Control Infants 
Ethanol Intake 
Samples were collected from two populations: 
 
• Study #1:  Neonates (n=3) who received either oral phenobarbital (15% 
ethanol, q12hr) and/or oral dexamethasone (30% ethanol, q12hr) per 
standard of care were eligible for enrollment.  A maximum of 6 blood 
samples/patient were taken over the study period.  Blood samples were 
collected via heel stick at the time of clinical laboratory collections or 
following a specific collection for study purposes.   
• Inclusion Criteria:  age <1 year, on any oral ethanol containing 
medication 
 
• Study #2: Neonates receiving sublingual buprenorphine (n=12, 30% ethanol, 
q8hr)  or morphine (n=14, control, no ethanol) for neonatal abstinence 
syndrome (NAS) from a separate clinical study (NCT01452789).   
• Inclusion Criteria:  ≥37 weeks gestation, exposure to opiates in 
utero, signs and symptoms of NAS requiring treatment 
 
• Blood ethanol levels were measured using a validated headspace gas 
chromatography-mass spectrometry method utilizing micro-volume (  ̴100uL) 
plasma samples.  The limit of detection (LOD) and lower limit of 
quantification (LLOQ) for the assay were 0.1 mg/L and 0.5 mg/L respectively.   
 
 
• Ethanol intake secondary to medication administration varied widely, but was generally low 
• Endogenous ethanol generation is present in non-ethanol treated infants (43% of samples ≥LLOQ) 
• Blood ethanol levels in neonates were low and ethanol was eliminated rapidly after a single dose of oral 
medications that contained a sizable fraction of ethanol    
- All blood ethanol levels were below the American Academy of Pediatrics recommendation following a 
single dose of an ethanol containing medication  
- Approximately one third of blood ethanol levels were above the European Medicines Agency 
recommendation following a single dose of an ethanol containing medication 
 
Figure 6.  Ethanol content of select oral pediatric 
medications available at Thomas Jefferson University.  
Ethanol content is expressed as w/v.  
• Develop a population pharmacokinetic model to describe ethanol pharmacokinetics 
 
Concentration (mg/L) Occurrence 
0-0.5 12 
0.5-1.0 3 
1.0-5.0 6 
5.0-10.0 1 
10.0-20.0 3 
20.0-30.0 2 
30.0-40.0 1 
40.0-50.0 1 
50.0-60.0 1 
60.0-70.0 0 
70.0-80.0 0 
80.0-90.0 1 
Total 31 
19 points >LLOQ from 
9 patients 
Total: 31 points 
from 12 patients  
15 patients 
39 points 
Buprenorphine (SL) 
8 patients 
16 points 
Phenobarbital (oral) 
3 patients 
13 points 
Buprenorphine & 
Phenobarbital* 
3 patients 
8 points 
8 points >LLOQ 11 points >LLOQ 7 points >LLOQ 
Dexamethasone (oral) 
2 patients 
2 points 
0 points >LLOQ 
Blood ethanol levels 
ranged from 0.63 to 28.4 
mg/L 
Blood ethanol levels 
ranged from 0.55 to 85.4 
mg/L 
Blood ethanol levels 
ranged from 0.63 to 
68.1 mg/L 
Figure 7.  Mean ethanol intake (mg/kg/dose) over the duration of sample collection.  Four 
neonates were exposed to phenobarbital and/or dexamethasone, while eleven neonates 
were exposed to buprenorphine alone or in combination with phenobarbital.   
Conclusions Figure 1.  Ethanol disposition in adults.  The red boxes indicate physiologic factors that have the  potential to affect the 
absorption, distribution, metabolism, and excretion of ethanol in neonates when compared to adults.    
Background 
Figure 9:  Concentration-time plots for buprenorphine only and phenobarbital only neonates.  (A) Breakdown of samples.  (B) Concentration time 
profile for all samples (above and below LLOQ). (C) Dose normalized concentrations of buprenorphine and phenobarbital.   
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• Ethanol is rapidly eliminated and does not accumulate with the current dosing regimens 
• Patients were exposed to a wide range of ethanol after a 
single dose of an ethanol containing medication  
     -Range 13.1 to 215 mg/kg/dose ethanol 
 
• Neonates received the greatest amount of ethanol in a 
single dose from phenobarbital 
1. Jones AW, Mårdh G, Anggård E. Determination of endogenous ethanol in blood and breath by gas 
chromatography-mass spectrometry. Pharmacol Biochem Behav. 1983;18 Suppl 1:267-72.        
 
• Approximately one third (13/39) of the blood alcohol 
levels were below the lower limit of quantification 
 
• Blood ethanol levels ranged from below detection to 
85.4 mg/L 
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Organization Year Recommendation 
American Academy of Pediatrics1 1984 
Blood ethanol levels should not exceed 250mg/L following a 
single dose of  an alcohol containing medication 
Code of Federal Regulations, 21 CFR 328 1995 
Any over the counter product shall not contain >0.5% alcohol 
as an inactive ingredient in children <6 years 
European Medicines Agency2 2014 
Blood ethanol levels should not exceed 10mg/L in children <6 
years of age 
Figure 2.  Recommended ethanol limits for pediatrics.  The American Academy of Pediatrics, Food and Drug 
Administration, and European Medicines Agency have all taken action, by either setting limits of ethanol content in 
over-the-counter medications or by recommending restricted exposure to ethanol containing pediatric formulations.   
Endogenous Ethanol 
Production 
1.  Ethanol in liquid preparations intended for children. Pediatrics. 1984 Mar;73(3):405-7. 
2.  Committee for Human Medicinal Products (CHMP). Questions and answers on ethanol in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for 
human use’ (CPMP/463/00).  
 
 
• 80% of the samples had detectable blood ethanol levels (≥LOD) 
• 43% of the samples had quantifiable blood ethanol levels (≥LLOQ) 
 
Figure reproduced from:  Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res Clin Exp. 2014 Oct 22;76:90-7. 
Figure reproduced from:  Marek E, Kraft WK. Ethanol pharmacokinetics in 
neonates and infants. Curr Ther Res Clin Exp. 2014 Oct 22;76:90-7. 
Figure 5.  Patient baseline characteristics (at first blood draw) in Study #2.  
